Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells

被引:7
|
作者
Klaihmon, Phatchanat [1 ]
Kang, Xing [1 ]
Issaragrisil, Surapol [1 ,2 ,3 ]
Luanpitpong, Sudjit [1 ,4 ]
机构
[1] Mahidol Univ, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Siriraj Hosp, Bangkok 10700, Thailand
[2] Mahidol Univ, Fac Med, Dept Med, Div Hematol,Siriraj Hosp, Bangkok 10700, Thailand
[3] Wattanosoth Canc Hosp, BDMS Ctr Excellence Hematol, Bangkok 10310, Thailand
[4] Mahidol Univ, Fac Med, Blood Prod & Cellular Immunotherapy Res Grp, Siriraj Hosp, Bangkok 10700, Thailand
关键词
chimeric antigen receptor; induced pluripotent stem cell; natural killer cell; anti-CD19; CAR; leukemia; CAR-NK; NK differentiation; DIFFERENTIATION; CANCER; MEMORY;
D O I
10.3390/ijms241310508
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Natural killer (NK) cells are a part of innate immunity that can be activated rapidly in response to malignant transformed cells without prior sensitization. Engineering NK cells to express chimeric antigen receptors (CARs) allows them to be directed against corresponding target tumor antigens. CAR-NK cells are regarded as a promising candidate for cellular immunotherapy alternatives to conventional CAR-T cells, due to the relatively low risk of graft-versus-host disease and safer clinical profile. Human induced pluripotent stem cells (iPSCs) are a promising renewable cell source of clinical NK cells. In the present study, we successfully introduced a third-generation CAR targeting CD19, which was validated to have effective signaling domains suitable for NK cells, into umbilical cord blood NK-derived iPSCs, followed by a single-cell clone selection and thorough iPSC characterization. The established single-cell clone of CAR19-NK/iPSCs, which is highly desirable for clinical application, can be differentiated using serum- and feeder-free protocols into functional CAR19-iNK-like cells with improved anti-tumor activity against CD19-positive hematologic cancer cells when compared with wild-type (WT)-iNK-like cells. With the feasibility of being an alternative source for off-the-shelf CAR-NK cells, a library of single-cell clones of CAR-engineered NK/iPSCs targeting different tumor antigens may be created for future clinical application.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
    Li, Sujun
    Xue, Lei
    Wang, Min
    Qiang, Ping
    Xu, Hui
    Zhang, Xuhan
    Kang, Wenyao
    You, Fengtao
    Xu, Hanying
    Wang, Yu
    Liu, Xin
    Yang, Lin
    Wang, Xingbing
    ONCOTARGETS AND THERAPY, 2019, 12 : 5627 - 5638
  • [32] Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
    Rossi, John
    Paczkowski, Patrick
    Shen, Yueh-Wei
    Morse, Kevin
    Flynn, Brianna
    Kaiser, Alaina
    Ng, Colin
    Gallatin, Kyle
    Cain, Tom
    Fan, Rong
    Mackay, Sean
    Heath, James R.
    Rosenberg, Steven A.
    Kochenderfer, James N.
    Zhou, Jing
    Bot, Adrian
    BLOOD, 2018, 132 (08) : 804 - 814
  • [33] Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
    Morita, Daisuke
    Nishio, Nobuhiro
    Saito, Shoji
    Tanaka, Miyuki
    Kawashima, Nozomu
    Okuno, Yusuke
    Suzuki, Satoshi
    Matsuda, Kazuyuki
    Maeda, Yasuhiro
    Wilson, Matthew H.
    Dotti, Gianpietro
    Rooney, Cliona M.
    Takahashi, Yoshiyuki
    Nakazawa, Yozo
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2018, 8 : 131 - 140
  • [34] Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells.
    Bot, Adrian
    Kochenderfer, James
    Mardiros, Armen
    Perez, Arianne
    Navale, Lynn
    Chang, Richard
    Yueh Wei-Shen
    Yoder, Sean
    Jia Xiao-Chi
    Rosenberg, Steven A.
    Go, William Y.
    Wiezorek, Jeffrey S.
    Roberts, Margo
    Chang, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Generation of functional podocytes from human induced pluripotent stem cells
    Ciampi, Osele
    Iacone, Roberto
    Longaretti, Lorena
    Benedetti, Valentina
    Graf, Martin
    Magnone, Maria Chiara
    Patsch, Christoph
    Xinaris, Christodoulos
    Remuzzi, Giuseppe
    Benigni, Ariela
    Tomasoni, Susanna
    STEM CELL RESEARCH, 2016, 17 (01) : 130 - 139
  • [36] Generation and Characterization of Human Induced Pluripotent Stem Cells
    Shutova, M. V.
    Bogomazova, A. N.
    Lagarkova, M. A.
    Kiselev, S. L.
    ACTA NATURAE, 2009, 1 (02): : 91 - 92
  • [37] Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
    Ghobadi, Armin
    Bachanova, Veronika
    Patel, Krish
    Park, Jae H.
    Flinn, Ian
    Riedell, Peter A.
    Bachier, Carlos
    Diefenbach, Catherine S.
    Wong, Carol
    Bickers, Cara
    Wong, Lilly
    Patel, Deepa
    Goodridge, Jode
    Denholt, Matthew
    Valamehr, Bahram
    Elstrom, Rebecca L.
    Strati, Paolo
    LANCET, 2025, 405 (10473): : 127 - 136
  • [38] Efficient generation of functional pancreatic β-cells from human induced pluripotent stem cells
    Yabe, Shigeharu G.
    Fukuda, Satsuki
    Takeda, Fujie
    Nashiro, Kiyoko
    Shimoda, Masayuki
    Okochi, Hitoshi
    JOURNAL OF DIABETES, 2017, 9 (02) : 168 - 179
  • [39] Targeting Cardiac Fibrosis with Chimeric Antigen Receptor Neutrophils from Human Pluripotent Stem Cells
    Jin, Gyuhyung
    Bao, Xiaoping
    CIRCULATION, 2024, 150
  • [40] Generation and Functional Characterization of Induced Pluripotent Stem Cells From Human Intervertebral Disc Nucleus Pulposus Cells
    Wu Zhang-Song
    Luo Zhi-Qiang
    Zhang Ming-Yu
    Lian Cui-Hong
    Lin Xin-Yan
    Liang Yu-Hong
    Gu Hong-Sheng
    Zhu Yan-Xiao
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2017, 44 (07) : 591 - 600